. 2012 Mar;340(3):612–619. doi: 10.1124/jpet.111.189100

TABLE 1.

Similar reduction in haloperidol-induced VCMs with chronic nicotine treatment (2 mg/kg per day) in the light or dark phase of the light-dark cycle

Rats were rated for haloperidol-induced VCMs in the light or dark phase of the daily cycle as described under Materials and Methods. Values are the mean ± S.E.M. of six rats in the vehicle and nicotine-treated and 12 rats in the haloperidol and nicotine + haloperidol-treated groups.

Lighting Condition	Treatment	Number of VCMs per 5 Min
Lighting Condition	Treatment	Control	Haloperidol
Light	Vehicle	0.4 ± 0.2	17.8 ± 2.9^###
	Nicotine	0.3 ± 0.2	6.6 ± 1.5^***
Dark	Vehicle	0.2 ± 0.2	13.4 ± 1.7^###
	Nicotine	0.1 ± 0.1	4.9 ± 0.8^#^***

Significance of difference from vehicle-treated control, # P < 0.05, ### P < 0.001; from vehicle-treated group, *** P < 0.001 using two-way ANOVA followed by a Bonferroni's post hoc test.